Anthem’s 43.4% EBITDA Margin and Unit 4 Capex Plan

Anthem Biosciences Limited — Q4 & FY26 Earnings Call (May 20, 2026)

1. Overall Tone of Management: Optimistic

• Management repeatedly emphasizes “very strong note,” “highest revenue quarter ever,” and “very confident” growth trajectory.
• They highlight margin expansion (“EBITDA margins of 43.4%… 420 basis points”) and strong balance sheet (“Net cash position… Rs. 1,375 crores”).
• They avoid quantitative FY27/FY28 guidance but still project confidence via qualitative statements (“mostly it’s behind us” on destocking; “capacity will not be a constraint”).

2. Key Themes from Management Commentary

• Strong FY26 performance + margin expansion
• FY26 consolidated revenue from operations: Rs. 2,124 cr; total revenue: Rs. 2,280 cr (+18%)
• EBITDA: Rs. 990 cr, 43.4% margins; PAT: Rs. 592 cr (+31%)
• CRDMO growth resilience despite destocking
• CRDMO delivered 83% of revenue and 18% FY growth; Q4 CRDMO +31% YoY
• Management claims destocking is “mostly behind us” and expects restocking to support top-line.
• Capacity expansion as the core growth engine
• Unit 2 expansion (+50% capacity) and Unit 3 commissioned
• Unit 4 framed as “future-ready” and the largest project; capacity headroom exists until Unit 4 comes online.
• Technology-led differentiation
• Focus on “continuous” processing, “better automation and control,” and “green chemistry” at commercial scale.
• AI discussed as “case by case,” mainly to optimize routes and plant operations rather than replace manufacturing.
• Selective inorganic growth posture
• “Not averse to looking at acquisitions,” but only if “right asset” (no acquisition “for the sake of an acquisition”).
• Specialty ingredients narrative: patchiness explained by cannibalization
• Management attributes earlier flatness to CRDMO taking priority in shared facilities; dedicated Unit 4 facility should improve growth consistency.

3. Q&A Analysis

Theme A: FY27 growth, destocking normalization, and CRDMO demand

• Core questions
• Expected CRDMO growth in FY27 (R&D + manufacturing).
• Whether destocking impacts on key molecules are “sorted” and growth returns.
• Management response
• Growth aspiration: “delivered growth in the vicinity of 20% and more” and “aspire to even in the coming years.”
• Destocking: “mostly it’s behind us” and when “destocking… swings to restocking,” Anthem should be “even in a better place.”
• Reiterated no FY27/FY28 guidance, but confidence in trajectory.
• Assessment
• Strong/committed language on destocking normalization, but no quantified demand outlook.
• Some hedging via “remains to be seen” and refusal to give guidance.

Theme B: Customer expansion (big pharma relationships) + capacity constraints

• Core questions
• How Anthem broadens relationships with more large innovators/big pharma.
• Whether capacity limits growth and whether new capacity will unlock more big pharma share.
• Management response
• Big pharma additions: two direct relationships last year; “growing healthily” but “not like flipping a switch.”
• Capacity: “I don’t see… capacity… a constraint” due to Unit 2/3 headroom until Unit 4.
• Assessment
• Clear operational confidence; no evidence of demand being constrained by capacity.
• Some process-based realism (“customers build confidence… slowly”)—not purely promotional.

Theme C: Strategic “missing pieces” (agility, technology, inorganic options)

• Core questions
• What’s missing to become “agile, science-led, future-ready” (organic/inorganic; India vs abroad).
• Capex and medium-term investment outlook.
• Management response
• Technology roadmap: automation/control, continuous processing, green chemistry at commercial scale.
• Acquisitions: actively scouting; won’t do it “for the sake of an acquisition.”
• Capex: Unit 4 is the major driver; ~Rs. 1,200 cr across FY27–FY28; capex next year ~Rs. 700 cr, then ~Rs. 500 cr.
• Assessment
• Detailed capex quantification is a strong answer.
• “Actively searching” acquisitions is directional, not specific.

Theme D: Product/modality mix (peptides, ADC payloads, biologics vs chemical)

• Core questions
• RFQ modalities (biological vs chemical).
• ADC payload development and manufacturing revenue split (biologics vs chemical).
• Management response
• RFQs: “Both” (custom synthesis + biology; peptides/RNAi).
• ADC payloads: “not at a liberty to disclose… confidential”; claims 15–20 payloads worked on.
• Revenue split: difficult to separate cleanly; “sizeable portion” from NCE custom synthesis; peptides/enzymatic/biotransformation blur categorization.
• Assessment
• Evasive/limited disclosure on ADC payload specifics (confidentiality).
• Revenue split answer is partially non-quantitative due to overlap in work types.

Theme E: GLP-1 opportunity, inventory risk, and differentiators

• Core questions
• Any remaining destocking/inventory risk.
• GLP-1 opportunity size, growth rate, and differentiation.
• Management response
• Destocking: “already happened… restocking now.”
• GLP-1: positioned as an India-based alternative to China-linked approvals; “good place to replace imports” after launches.
• Differentiation: focus on small biotechs/discovery side, technology solutions, and culture/ESOP-driven workforce.
• Assessment
• Strong qualitative confidence; no numbers on GLP-1 market size or growth rate.
• “After most of them have launched…” implies timing dependency.

Theme F: Margins sustainability and gross margin drivers

• Core questions
• Whether fungible gross block affects margins; what EBITDA margin to assume.
• CRO/gross margin drivers and revenue mix.
• Management response
• Margin stance: costs scale with growth; “operating leverage” should keep margins constant; expects 38–40% EBITDA.
• Gross margin improvement: backward integration completed for an intermediate; improved material margins in Q3/Q4.
• Revenue mix: commercial ~60%, late-stage 14%, R&D 8–9%, specialty ingredients ~17%; development/manufacturing batches ~15%.
• Assessment
• Quantitative margin range provided (38–40%).
• Credibility supported by a concrete driver (backward integration completion).

Theme G: Large molecule CRDMO readiness + biosimilar progress

• Core questions
• Willingness of innovators to outsource large molecule to India; cost advantage vs Korea/China.
• Biosimilar asset progress and classification (CRDMO vs specialty ingredients).
• Management response
• Willingness: “no problem… problem… is capacities” in Korea/China; Anthem investing for large molecules.
• Large molecule projects: 4–5 projects where Anthem expects development partner/manufacturing partner role.
• Biosimilar: “going really well,” refiled three batches; lead time ~one year; “hit our P&L next year,” likely classified under CRDMO.
• Assessment
• Strong operational explanation; no cost advantage quantified (acknowledges upfront investment scale).

4. Guidance / Outlook

Explicit guidance (quantitative)

• Capex
• Unit 4 Phase 1: ~Rs. 1,200+ cr across FY27 and FY28
• FY27 capex: “Roughly about Rs. 700 crores”
• Post FY27: “about Rs. 500 crores”
• Unit 4 Phase 1 completion: “by March ’28… towards the latter half”
• Capacity additions (Unit 4 Phase 1)
• Custom synthesis: +~365 kiloliters
• Fermentation: +~100 kiloliters
• Stated vs current: current 425 kL custom synthesis and 180 kL fermentation
• Margin expectation
• EBITDA margin “38% to 40%” (asked directly; management agreed “we’ll continue to deliver those numbers”)
• Timing
• Unit 4 ready: “by the next financial year” (closing remarks)
• Biosimilar P&L impact: “next year” (lead time ~one year)

Implicit signals (qualitative)

• Growth
• Aspiration to maintain long-term ~20%+ growth trajectory; FY27 confidence but no numeric guidance.
• Destocking
• Destocking “mostly behind us”; restocking expected to be positive for topline/bottomline.
• Demand visibility
• “Customers… more projects,” “commercial portfolio increased,” late-stage portfolio increased.
• AI
• AI adoption is selective (“case by case”), with manufacturing optimization as a margin lever.
• Specialty ingredients
• Dedicated facility in Unit 4 should reduce cannibalization and support more consistent growth.

5. Standout Statements (directly revealing)

• Destocking normalization
• “mostly it’s behind us” and “we expect… very positive impact on Anthem’s top line and bottom line.”
• Capacity not a constraint
• “I don’t see… capacity… a constraint… we have a decent headroom right now… till the time our Unit 4 comes up.”
• Unit 4 scale
• “Unit 4… is going to be much larger than all the units put together.”
• Capex magnitude
• “investing almost about Rs. 1,200 odd crores across two years” (FY27–FY28).
• Margin stance
• “38% to 40% EBITDA margins is a fair number to assume” → “we’ll continue to deliver those numbers.”
• Acquisitions discipline
• “We will not do an acquisition for the sake of an acquisition. It has to make sense.”
• Biosimilar timing
• “Typically… lead times… tends to be one year or so… I think… will hit our P&L next year.”
• GLP-1 timing dependency
• “this will be in the after most of them have launched” (implies ramp depends on customer approvals/launches).

6. Red Flags / Positive Signals

Red flags
– No FY27/FY28 quantitative guidance despite multiple questions on growth and GLP-1 opportunity size.
– Confidentiality limits on ADC payload details; modality mix answers are non-quantitative due to overlap.
– Timing risk implied for GLP-1 and commercial ramp (“could happen in six months… eight months”; ramp-up “two to three years”).

Positive signals
– Concrete capex plan with quantified amounts and capacity additions.
– Margin confidence backed by an operational driver (backward integration completion).
– Restocking/demand recovery narrative is consistent across multiple analysts.
– Biotech funding recovery: “up by about 50-odd percent YoY” (supports inquiry flow).

7. Historical Comparison & Consistency Analysis

Note: No prior earnings call transcripts were provided (“No documents matched the configured filters”), so historical comparison cannot be performed.

a. Change in Tone Over Time

• Not assessable (no prior transcripts available).

b. Tracking Past Commitments vs Outcomes

• Not assessable (no prior transcripts available).

c. Narrative Shifts

• Not assessable (no prior transcripts available).

d. Consistency & Credibility Signals

• Limited to this call only: management provides specific capex/margin numbers and explains margin drivers (backward integration), which supports credibility within the call.

e. Evolution of Key Themes

• Not assessable across calls.

f. Additional Insights (Cross-Period Intelligence)

• Not assessable without prior transcripts.